Zejing Pharmaceutical: Injectable ZGGS34 has obtained a drug clinical trial approval notification.

Zejing Pharmaceutical announced that the company has received the "Notice of Approval for Drug Clinical Trial" issued by the National Medical Products Administration. The clinical trial of injection ZGGS34 for MUC17-positive advanced solid tumors has been approved. This drug is a tri-specific antibody drug with strong tumor-killing effects and good safety features.